Suppr超能文献

中药扶正化瘀促进人胚胎干细胞向肝细胞分化

Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu.

作者信息

Chen Jiamei, Gao Wei, Zhou Ping, Ma Xiaocui, Tschudy-Seney Benjamin, Liu Chenghai, Zern Mark A, Liu Ping, Duan Yuyou

机构信息

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Department of Internal Medicine, University of California Davis Medical Center, Sacramento, California, USA.

出版信息

Sci Rep. 2016 Jan 6;6:18841. doi: 10.1038/srep18841.

Abstract

Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY's role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.

摘要

中药扶正化瘀(FZHY)似乎可防止人类肝纤维化进展并改善肝功能。我们在此发现,FZHY可增强人胚胎干细胞(hESC)向肝细胞的分化。用FZHY处理后,在分化和成熟过程中白蛋白表达持续增加,代谢酶和转运蛋白的表达也增加。重要的是,用FZHY处理可显著降低间充质细胞和胆管细胞标志物的表达,这表明FZHY发挥作用的一种可能机制是抑制间充质细胞和胆管细胞的形成。Edu标记的流式细胞术分析表明,处理后的细胞中Edu阳性细胞的百分比增加。这些结果表明,增殖增强涉及肝细胞而非其他细胞类型。我们的研究进一步揭示,FZHY的这些增强作用是通过激活经典Wnt和ERK途径以及抑制Notch途径介导的。因此,FZHY不仅促进肝细胞分化和成熟,还增强肝细胞增殖。这些结果表明,FZHY似乎是治疗肝纤维化的一种优秀治疗药物,并且FZHY治疗可增强我们为基于细胞的治疗以及药理和毒理学研究生成具有增殖能力的成熟肝细胞的努力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf2/4702137/0427e8f9b4a3/srep18841-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验